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The ideal gold standard for purposes of human 
tissue engineering/regeneration are deemed to 
be biomaterial nanofiber scaffolds endowed 
with a set of optimized features in connection 
with surface properties, biocompatibility, gas 
permeability, biodegradability, mechanical 
strength, immunogenicity, foreign body re-
sponse (FBR), and release of growth factor(s) 
and/or drug(s). Amid the biomaterials candidat-
ing for such nanofiber scaffolds, the silk fibroin 
proteins (SFs), have been objects of a growing 
interest [1,2], as demonstrated by the trend of 
the number of publications appeared in the sci-
entific literature during the last ten years (Figure 
1). SFs are natural proteins produced by wild 
and domesticated silkworms, spiders, honey-
bees, wasps, and ants [3-7]. Variants of SFs 
have been genetically engineered to produce 
novel biomaterials [8]. They share repetitive 
amino acid sequences of the poly(Ala) or poly
(Gly-Ala) type arranged in antiparallel beta-sheet 
structures [9], are biodegradable in vitro and in 
vivo [10-13], very little inflammogenic [14,15] 
and can be electrospun into pure SF nanofibers 
[16-22] or blended with other biomaterials, e.g. 
poly(L-lactic acid), poly(ethylene oxide), poly(-
caprolactone), hydroxybutyl chitosan, heparin, 
collagen, gelatin, etc. [23-37].  
 
The electrospun SF scaffolds have been re-
ported to exhibit good cell biocompatibility [38] 
and their structure and physicochemical fea-
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Figure 1. Trend of publications on SF nanofiber scaf-
folds for biomedical applications 
 
Fibroin nanofiber scaffolds and regenerative medicine 
 
 
28                                                                                                                 Int J Burn Trauma 2011;1(1):27-33 
tures were shown be deeply influenced by the 
treatments SF undergoes prior to and/or during 
electrospinning [4,21,25,39-41]. Application of 
SF nanofiber scaffolds has been suggested for 
the engineering and regeneration of both soft 
tissues, like vascular grafts, nerves, skin 
wounds [42-54], and hard tissues, like tendons, 
ligaments, bone and cartilage [16,55-65], al-
though in the latter instances SF was also used 
as microfiber or sponge and mixed with other 
biomaterials. In these tissue regeneration at-
tempts bone marrow mesenchymal stem cells 
have often been seeded onto the scaffolds to 
observe their differentiation into the several 
types of the connective tissue or into Schwann 
peripheral nerve cells [49]. To enhance cell ad-
hesion, spreading, and proliferation, SF nanofi-
ber scaffolds were also functionalized with vari-
ous bioactive peptides (RGD, BMP, etc.) 
[16,54,66]. 
 
Notably, most if not all of the authors claim to 
have been successful in their endeavors. So, 
why the SF nanofiber scaffolds have not as yet 
found their way to the application in the clinical 
settings? 
 
What is missing? 
 
It should not be overlooked that most of the 
published studies on the topic mainly concern 
the still ongoing efforts to improve the technical 
procedures used to prepare the scaffolds and 
hence the scaffolds themselves and to assess 
their physicochemical properties. Conversely, 
the interactions of the scaffolds with living cells 
in vitro or in vivo, especially the long-term ones, 
often if not mostly appear as shallow append-
ages of the biomaterialistic studies. Is this an 
indication that we are still in too an early phase 
to have set up appropriate scaffolds? This sci-
entific “immaturity” is moreover compounded by 
the fact that the biological tests have been pref-
erentially carried out on rodent cells of rats or 
mice, indeed imperfect mirrors of the corre-
sponding human tissues. In such models, the 
local and general responses to the implanted 
SF nanofiber scaffolds, as well as the timing 
and rates of the degradation of the latter have 
been poorly assessed. On the whole, while the 
technically complex questions related to the 
characteristics and production of the nanofiber 
scaffolds keep being targeted, the as well or 
even more intricate biological interactions of the 
same scaffolds with living cells, tissues, and 
organisms have by and large remained in the 
shades. This has somewhat delayed or ham-
pered the onset of an applicative era for the SF 
nanofiber scaffolds. As a consequence, in some 
people, this has generated the idea that SFs are 
old-fashioned biomaterial relics, interesting 
maybe but not so functional: hence, they should 
be superseded by novel, more fashionable, and 
more readily applicable biomaterials. 
 
What the remedy might be? 
 
In the opinion of the authors, this negative out-
look is hasty and not founded enough. First of 
all, it should be recalled here that many human 
proteins expressed by both epithelial and con-
nective tissue cells exhibit biologically signifi-
cant (i.e., with very low E-Values and P values) 
homology sequences with heavy-chain B. mori 
SFs (just as an example, see the 49 human pro-
teins listed in Table 1). Such proteomic data 
underlie the reason why surgical stitches made 
of degummed (sericin-deprived) SF are not im-
munogenic in humans [67]. In addition, SF-
based scaffolds have been shown to favor an-
giogenesis, an feature essential for tissue re-
pair/regeneration [15,68]. Hence, these impor-
tant pieces of evidence are not to be overlooked 
in the perspective of the clinical application of 
SF-based scaffolds. Moreover, a huge hoard of 
promising data concerning SF-based biomate-
rials has been accumulating during recent 
years. To make the jump to the applicative set-
tings some more technological improvement 
leading to more robust and reliable production 
techniques, a deeper knowledge of structure/
function relationship of SF nanofiber scaffolds 
and, as mentioned above, an increase in the 
understanding of the biological interactions are 
all is needed. Therefore, to seriously overcome 
such hurdles and reach a definitive assessment 
of the opportunities (or, unluckily, lack of them) 
of the SF nanofiber scaffolds in human tissue 
repair/regeneration, it should be realized that 
biomaterialists and cell/tissue/animal/human 
biology experts must solidly cooperate with each 
other while absolutely avoiding the hard to re-
sist temptation to assume each other’s role, as 
the skills required for either job are highly com-
plex and specific. By each one sticking to his/
her respective role, it would be easier to carry 
out compound and articulated research projects 
aimed at scalarly optimizing and standardizing 
the SF nanofiber scaffolds according to the tar-
gets they are aimed at (wound healing, chondro-
genesis, osteogenesis, etc.). These major re-
search projects would entail several successive 
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rounds of structural and functional improve-
ment of the SF nanofiber scaffolds based upon 
the results gained by assessing both in vitro and 
in vivo the biological properties of their previous 
versions. Thus, through the proper use of the 
specific expertise of either group, the time re-
quired to attain optimized (or nearly so) scaf-
folds should be significantly shortened. This 
recursive testing and optimization of the scaf-
folds would finally open the way to preclinical 
testing of the optimized scaffolds in large mam-
mals (e.g. dog, sheep, etc.). The assessment of 
the local tissue engineering/regeneration and 
local inflammatory and FBR responses and of 
Table 1. A partial list of human proteins endowed with biologically significant sequence homologies to heavy-chain SF 
from B. mori  
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general immunological (if any) reactions to the 
grafted scaffolds in such mammals would allow 
their definitive optimization. At this step, phase I 
clinical trials on selected cohorts of human pa-
tients would be feasible and fully justified, and 
their results would (or would not) lead further to 
phase II and III clinical trials and, eventually, to 
the approval of the scaffolds in their final formu-
lations for human use by the FDA. It is implicit 
that to implement such a scheme large mone-
tary resources would be needed and the col-
laboration between international research 
groups more than welcome would be manda-
tory. 
 
Conclusions 
 
On the basis of the available lines of evidence, 
SF proteins, especially the most studied ones 
from B. mori and spiders, and their genetically 
recombinant forms can still be considered as 
promising tools and not outdated biomaterials, 
for human tissue engineering/regeneration. But 
it is clear that efforts on a much greater scale 
than up till now are needed to definitively as-
sess the effective usefulness of such tools, 
thereby allowing (or negating) their successful 
introduction into the fields of Translational Re-
generative Medicine (i.e. from the lab bench to 
the patient’s bed). A factor complicating the 
picture is that the SF nanofiber scaffolds may 
contain additional biomaterials and be molded 
into manifold morphologies according to their 
specific aims. No doubt, these efforts require 
the wide cooperation of international groups 
with deep specific expertise in their respective 
fields, i.e. biomaterial technologies and animal 
and human cell and tissue biopathology, respec-
tively. To such projects private firms should also 
partake given the huge economic interests in-
volved if the translation of SF-based nanofiber 
scaffolds to the clinical settings is made possi-
ble. 
 
Unavoidably, the incessant discovery of novel 
biomaterials other than the SFs, while advanc-
ing our knowledge in basic sciences, takes away 
scientists and resources from more deeply fo-
cusing on the potential applications of the SF 
nanofiber scaffolds. But the biological features 
of these newly discovered biomaterials are not 
generally studied in greater depth either. Hence, 
from the standpoint of Translational Regenera-
tive Medicine, it remains undecided whether 
eventually they might or not be superior to the 
SF nanofibers. Therefore, although the currently 
available choices are manifold, it is conceivable 
that a considerable loss for Human (and Veteri-
nary Medicine) could stem from not fully investi-
gating the real clinical opportunities well de-
vised and tested SF nanofiber scaffolds would 
be likely to offer. 
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